We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Clinical Trials for Cholesterol, Cardiovascular Drugs Halted
Clinical Trials for Cholesterol, Cardiovascular Drugs Halted
November 14, 2007
The FDA has recommended that Takeda Pharmaceutical halt high-dose trials of its cholesterol drug TAK-475 due to concerns over possible liver damage, and Daiichi Sankyo and Eli Lilly are suspending patient enrollment and dosing in two small clinical trials of their investigational antiplatelet drug prasugrel until protocol amendments can be completed and approved.